US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on behalf of Grünenthal, it has emerged.
Mundipharma has signed a licensing and distribution deal with the German pharmaceutical firm which covers a number of forms of the medicine, including Tramal sustained release tablets, immediate release capsules and a post-operation intravenous formulation know3n as patient controlled intraveneous analgesia (PCIA). It will assume the duties from 1 May this year.
